o-Vanillin dosage and evidence

o-Vanillin is a natural cousin of vanillin, the vanilla smell chemical. It cleared worn-out 'zombie' cells from human spinal disc tissue in the lab, and eased pain behaviour in mice with back pain. It has never been given to a person in a study.

o-Vanillin is a chemical cousin of vanillin, the compound that gives vanilla its smell. Nearly everything known about it as a senolytic comes from one research program at McGill University. That program looks at one problem: worn-down spinal discs.

The reasoning is unusually concrete. Discs build up zombie cells. Those cells pump out signals that inflame the disc and break down its structure. Long-term low back pain is one of the most common and worst-treated problems in medicine. If zombie cells drive part of it, clearing them in one spot is easier than clearing them from the whole body.

There are no human studies, so the best work is on human tissue in the lab. The 2019 work compared curcumin and o-vanillin in cells taken from human discs, from organ donors and from people having surgery for low back pain. Worn discs had about 40 percent more zombie cells than healthy discs from other people, and about 10 percent more when compared within the same person. Both compounds cleared zombie cells, cut the inflammatory signals, and helped the cells build more disc tissue.

A 2020 paper in eLife went further. It compared o-vanillin with RG-7112, a lab-made drug, in whole worn human discs kept alive outside the body. A single dose helped the discs keep up their tissue, and that went along with fewer zombie cells and less inflammation. A 2021 paper showed that switching on an immune sensor called TLR-2 turned human disc cells into zombie cells, and that o-vanillin cut zombie cells, inflammatory signals and the sensor itself.

The first test in live animals came in 2025, in mice bred to get low back pain. They got o-vanillin and RG-7112 by mouth, alone and together. Pain behaviour dropped. Zombie cells were cleared from the disc and spinal cord. Inflammatory signals fell, disc wear scores dropped, spine bone quality improved, and pain markers in the spinal cord went down.

That is a clear program with a clear target, run by one group, all in cells, human tissue and mice. There is no human study.

There is no human evidence. No study of o-vanillin in people has been registered or published, so nothing here describes what it does in a living person.

Two things make this page worth reading anyway. First, the human tissue work is better than most early senolytic evidence. Cells came from known human donors and from patients having back surgery. Zombie cell numbers were counted within the same person as well as between people. And the 2020 work used whole human discs kept alive, not loose cells. That is much closer to a person than a cancer cell line. It is still not a person.

Second, money. o-Vanillin is a simple, cheap molecule nobody can patent. Nobody can own it, so nobody has a reason to pay for the study that would settle what it does. Its thin record is at least partly about money, not a verdict on the compound. The program's lab-made comparison drug, RG-7112, has been safety tested in people with cancer. That kind of imbalance shapes which senolytics ever get tested in people.

Senolytics are drugs meant to clear out worn-out 'zombie' cells, called senescent cells. No senolytic of any kind has yet made people better off in a proper human study against a dummy treatment. That is the most useful fact to carry into any senolytic talk. One pair, dasatinib plus quercetin, has lowered the number of zombie cells in people, measured in skin and fat samples. What has not followed is a study where people who got a senolytic walked further, broke fewer bones or lived longer than people who did not. The two studies against a dummy that tried, one in lung scarring (pulmonary fibrosis) and one on bone turnover after menopause, found no difference.